Moneycontrol
    Moneycontrol PRO

    Ajanta Orpat

    Jump to

    • Trade Spotlight: How should you trade Karnataka Bank, Torrent Power, JSW Energy, Ajanta Pharma, Supreme Industries, and others on February 6?

      The market may consolidate further as participants await the outcome of the RBI monetary policy meeting scheduled for February 6. Below are some short-term trading ideas to consider.

    • Buy Ajanta Pharma; target of Rs 3200: Prabhudas Lilladher

      Prabhudas Lilladher is bullish on Ajanta Pharma has recommended buy rating on the stock with a target price of Rs 3200 in its research report dated January 31, 2026.

    • Ajanta Pharma Consolidated December 2025 Net Sales at Rs 1,374.84 crore, up 19.95% Y-o-Y

    • Ajanta Pharma Standalone December 2025 Net Sales at Rs 1,206.59 crore, up 9.5% Y-o-Y

    • Buy Ajanta Pharma; target of Rs 3400: Motilal Oswal

      Motilal Oswal is bullish on Ajanta Pharma has recommended buy rating on the stock with a target price of Rs 3400 in its research report dated January 30, 2026.

    • Reduce Ajanta Pharma; target of Rs 2760: Choice Institutional Equities

      Choice Institutional Equities recommended reduce rating on Ajanta Pharma with a target price of Rs 2760 in its research report dated January 31, 2026.

    • Trade Spotlight: How should you trade Bajaj Auto, Ajanta Pharma, NLC India, Gujarat Gas, Wipro, and others on January 2?

      Consolidation with range-bound trading may continue for a couple of more sessions before the market regains strength. Below are some short-term trading ideas to consider.

    • Ajanta Pharma rises 3.5% as Motilal Oswal expects strong gains from new weight-loss drug, sees up to 17% upside

      Ajanta Pharma shares touched a high of Rs 2,784.80, up 3.52 percent. The scrip has risen for the last two trading sessions.

    • Buy Ajanta Pharma; target of Rs 3145: Motilal Oswal

      Motilal Oswal is bullish on Ajanta Pharma recommended buy rating on the stock with a target price of Rs 3145 in its research report dated December 29, 2025.

    • Buy Ajanta Pharma; target of Rs 3200: Prabhudas Lilladher

      Prabhudas Lilladher is bullish on Ajanta Pharma has recommended buy rating on the stock with a target price of Rs 3200 in its research report dated December 24, 2025.

    • Ajanta Pharma shares rise 5% on Biocon weight-loss drug marketing pact

      Biocon will supply Semaglutide to Ajanta Pharma for exclusive marketing in 23 countries and semi-exclusive marketing in three countries across Africa, West Asia, and Central Asia

    • Stocks to Watch Today: Monte Carlo, Belrise, Emcure Pharma, GPT Infra, Surana Telecom, Vikran Engineering, Federal Bank in focus on 24 December

      Stocks to Watch, 24 December: Stocks like Monte Carlo Fashions, Rail Vikas Nigam, Zydus Lifesciences, Emcure Pharmaceuticals, GPT Infraprojects, SJS Enterprises, Surana Telecom, Vikran Engineering, Ajanta Pharma, Coal India, Federal Bank, Bliss GVS Pharma, GAIL India, Belrise Industries, and Marc Technocrats will be in focus on December 24.

    • Ajanta Soya Standalone September 2025 Net Sales at Rs 346.93 crore, up 14.16% Y-o-Y

    • Reduce Ajanta Pharma: target of Rs 2,450: Choice

      Choice recommended reduce rating on Ajanta Pharma with a target price of Rs 2,450 in its research report dated November 04, 2025.

    • Ajanta Pharma Standalone September 2025 Net Sales at Rs 1,220.24 crore, up 8.09% Y-o-Y

    • Buy Ajanta Pharma; target of Rs 3000: Motilal Oswal

      Motilal Oswal is bullish on Ajanta Pharma has recommended buy rating on the stock with a target price of Rs 3000 in its research report dated November 01, 2025.

    • Ajanta Pharma Consolidated September 2025 Net Sales at Rs 1,353.73 crore, up 14.08% Y-o-Y

    • Buy Ajanta Pharma; target of Rs 3200: Prabhudas Lilladher

      Prabhudas Lilladher is bullish on Ajanta Pharma has recommended buy rating on the stock with a target price of Rs 3200 in its research report dated September 19, 2025.

    • Trade Spotlight: How should you trade Bayer Cropscience, Jindal Stainless, General Insurance Corp, HUL, Bharti Hexacom, JSW Steel and others on August 1?

      The bearish sentiment is expected to prevail until the frontline indices provide a sustainable close above the medium-term moving average. Below are some short-term trading ideas to consider.

    • Ajanta Pharma Consolidated June 2025 Net Sales at Rs 1,302.65 crore, up 13.78% Y-o-Y

    • Ajanta Pharma Standalone June 2025 Net Sales at Rs 1,208.56 crore, up 12.19% Y-o-Y

    • Trade Spotlight: How should you trade Ajanta Pharma, Hyundai Motor India, Max Healthcare Institute, Nelcast, Cera Sanitaryware and others on June 13?

      The market may attempt a rebound amid likely range-bound trading in the upcoming session, but the sustainability is the key watch. Below are some short-term trading ideas to consider.

    • Ajanta Soya Standalone March 2025 Net Sales at Rs 388.39 crore, up 61.81% Y-o-Y

    • Reduce Ajanta Pharma: target of Rs 2500: ICICI Securities

      ICICI Securities recommended reduce rating on Ajanta Pharma with a target price of Rs 2,500 in its research report dated May 01, 2025.

    • Ajanta Pharma Consolidated March 2025 Net Sales at Rs 1,170.41 crore, up 11.04% Y-o-Y

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347